Ganciclovir and the treatment of Epstein-Barr virus hepatitis.
Epstein-Barr virus (EBV) is part of the herpesvirus family that infects up to 90% of the population. Initial infection is often subclincal in children but will generally result in symptomatic infectious mononucleosis in adolescents and adults. Ganciclovir has been utilized in immunocompromised patients with EBV encephalitis and post-liver transplant for EBV fulminant hepatitis. Herein, the successful use of ganciclovir in two immunocompetent patients with severe EBV hepatitis is reported.
Adams
Leon A
LA
Department of Gastroenterology and Hepatology, Sir Charles Gardiner Hospital, Nedlands, WA, Australia. leon.adams@uwa.edu.au
Deboer
Bastiaan
B
Jeffrey
Gary
G
Marley
Richard
R
Garas
George
G
D000998:Antiviral Agents / Q000627:therapeutic use*; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy*; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use*; D006525:Hepatitis, Viral, Human / Q000188:drug therapy*; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged
D000998:Antiviral Agents; D015774:Ganciclovir